These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 7259691)
21. Evaluation of a new antinauseant drug for the prevention of motion sickness. Graybiel A; Knepton J Aviat Space Environ Med; 1977 Sep; 48(9):867-71. PubMed ID: 334151 [No Abstract] [Full Text] [Related]
22. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness. Wang ET; Zhou DR; He LH Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of antimotion sickness drug side effects on performance. Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169 [TBL] [Abstract][Full Text] [Related]
25. Side effects of antimotion sickness drugs. Wood CD; Manno JE; Manno BR; Redetzki HM; Wood M; Vekovius WA Aviat Space Environ Med; 1984 Feb; 55(2):113-6. PubMed ID: 6696702 [TBL] [Abstract][Full Text] [Related]
26. Results of a randomized double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis. Longo DL; Wesley M; Howser D; Hubbard SM; Anderson T; Young RC Cancer Treat Rep; 1982 Nov; 66(11):1975-6. PubMed ID: 6890407 [TBL] [Abstract][Full Text] [Related]
27. Transdermal scopolamine in the prevention of motion sickness at sea. Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021 [TBL] [Abstract][Full Text] [Related]
28. Transderm scopolamine efficacy related to time of application prior to the onset of motion. Levy GD; Rapaport MH Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572 [TBL] [Abstract][Full Text] [Related]
29. The effect of antimotion sickness drugs on habituation to motion. Wood CD; Manno JE; Manno BR; Odenheimer RC; Bairnsfather LE Aviat Space Environ Med; 1986 Jun; 57(6):539-42. PubMed ID: 3718377 [TBL] [Abstract][Full Text] [Related]
30. Transdermal scopolamine for motion sickness. Med Lett Drugs Ther; 1981 Oct; 23(21):89-90. PubMed ID: 7027000 [No Abstract] [Full Text] [Related]
31. Differential effects of scopolamine and amphetamine on microcomputer-based performance tests. Kennedy RS; Odenheimer RC; Baltzley DR; Dunlap WP; Wood CD Aviat Space Environ Med; 1990 Jul; 61(7):615-21. PubMed ID: 2386447 [TBL] [Abstract][Full Text] [Related]
33. Use of phenytoin in the prevention of motion sickness. Chelen W; Kabrisky M; Hatsell C; Morales R; Fix E; Scott M Aviat Space Environ Med; 1990 Nov; 61(11):1022-5. PubMed ID: 2256875 [TBL] [Abstract][Full Text] [Related]
35. A comparison of effectiveness of some antimotion sickness drugs using recommended and larger than recommended doses as tested in the slow rotation room. NSAM-945. Wood CD; Graybiel A; Kennedy RS Res Rep U S Nav Sch Aviat Med; 1965 Jul; ():1-9. PubMed ID: 5322559 [No Abstract] [Full Text] [Related]
36. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects. Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820 [TBL] [Abstract][Full Text] [Related]
37. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. Nachum Z; Shupak A; Gordon CR Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539 [TBL] [Abstract][Full Text] [Related]
38. Effects of transcutaneous scopolamine and depth on diver performance. Williams TH; Wilkinson AR; Davis FM; Frampton CM Undersea Biomed Res; 1988 Mar; 15(2):89-98. PubMed ID: 3363755 [TBL] [Abstract][Full Text] [Related]
39. Prevention and treatment of space sickness in shuttle-orbiter missions. Graybiel A Aviat Space Environ Med; 1979 Feb; 50(2):171-6. PubMed ID: 36067 [TBL] [Abstract][Full Text] [Related]
40. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time. Howland J; Rohsenow DJ; Minsky S; Snoberg J; Tagerud S; Hunt SK; Almeida A; Greece J; Allensworth-Davies D Int J Occup Environ Health; 2008; 14(4):250-6. PubMed ID: 19043911 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]